---
figid: PMC7305712__gr2_lrg
figlink: pmc/articles/PMC7305712/figure/f0010/
number: F2
caption: Altered signaling and pathogenic mechanisms in hepatocytes during NAFLD progression
  a) insulin signaling in healthy hepatocytes suppress endogenous glucose production
  through inhibition of gluconeogenesis and increasing glycogen synthesis b) steatotic
  hepatocytes are characterized by disturbed lipid metabolism i.e., 1) there is increase
  in FFA influx which enters the liver through fatty acid transport proteins (FATP)
  and leads to 2) increased mitochondrial fatty acid oxidation, 3) formation of lipid
  toxic intermediates e.g. sn 1,2 DAG which stimulates PKCε to phosphorylate Thr1160
  in insulin receptor leading to hepatic insulin resistance i.e., increased gluconeogenesis
  and decreased glycogen synthesis. Again, FFA metabolites e.g. acetyl CoA could directly
  stimulate gluconeogenesis [] 4) increased glucose enters the liver mainly through
  glucose transporter (GLUT2) and activates ChREBP pathway. Insulin-signaling activates
  SREBP1C pathway too. Both pathways increase DNL c) after progression to NASH, mitochondrial
  flexibility is lost leading to decreased fatty acid oxidation. Together with other
  toxic intermediate lipid, ER stress and ROS generation increase leading to hepatocytes
  death and release of inflammatory cytokines and chemokines. AKT, protein kinase
  B; ChREBP, carbohydrate response element-binding protein; DAG, sn 1,2 diacylglycerol;
  DNL, de novo lipogenesis; EGP, endogenous glucose production; ER, endoplasmic reticulum;
  FAO, fatty acid oxidation; FFA, free fatty acids; GLU, glucose; GNG, gluconeogenesis;
  INS, insulin; INS-R, insulin resistance; IR, insulin receptor; PI3K, phosphatidylinositol-3-kinase;
  PKC, protein kinase C; ROS, reactive oxygen species; SREBP1C; sterol regulatory
  element-binding proteins; TAG, triacylglycerol.
pmcid: PMC7305712
papertitle: Metabolic liver disease in diabetes – From mechanisms to clinical trials.
reftext: Bedair Dewidar, et al. Metabolism. 2020 Oct;111:154299-154299.
pmc_ranked_result_index: '6621'
pathway_score: 0.8619613
filename: gr2_lrg.jpg
figtitle: Metabolic liver disease in diabetes – From mechanisms to clinical trials
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7305712__gr2_lrg.html
  '@type': Dataset
  description: Altered signaling and pathogenic mechanisms in hepatocytes during NAFLD
    progression a) insulin signaling in healthy hepatocytes suppress endogenous glucose
    production through inhibition of gluconeogenesis and increasing glycogen synthesis
    b) steatotic hepatocytes are characterized by disturbed lipid metabolism i.e.,
    1) there is increase in FFA influx which enters the liver through fatty acid transport
    proteins (FATP) and leads to 2) increased mitochondrial fatty acid oxidation,
    3) formation of lipid toxic intermediates e.g. sn 1,2 DAG which stimulates PKCε
    to phosphorylate Thr1160 in insulin receptor leading to hepatic insulin resistance
    i.e., increased gluconeogenesis and decreased glycogen synthesis. Again, FFA metabolites
    e.g. acetyl CoA could directly stimulate gluconeogenesis [] 4) increased glucose
    enters the liver mainly through glucose transporter (GLUT2) and activates ChREBP
    pathway. Insulin-signaling activates SREBP1C pathway too. Both pathways increase
    DNL c) after progression to NASH, mitochondrial flexibility is lost leading to
    decreased fatty acid oxidation. Together with other toxic intermediate lipid,
    ER stress and ROS generation increase leading to hepatocytes death and release
    of inflammatory cytokines and chemokines. AKT, protein kinase B; ChREBP, carbohydrate
    response element-binding protein; DAG, sn 1,2 diacylglycerol; DNL, de novo lipogenesis;
    EGP, endogenous glucose production; ER, endoplasmic reticulum; FAO, fatty acid
    oxidation; FFA, free fatty acids; GLU, glucose; GNG, gluconeogenesis; INS, insulin;
    INS-R, insulin resistance; IR, insulin receptor; PI3K, phosphatidylinositol-3-kinase;
    PKC, protein kinase C; ROS, reactive oxygen species; SREBP1C; sterol regulatory
    element-binding proteins; TAG, triacylglycerol.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - INS
  - INSR
  - IRS2
  - PIK3CA
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3CB
  - PIK3CD
  - PIK3R5
  - PIK3R6
  - AKT2
  - AKT3
  - AKT1
  - MLXIPL
  - DNASE2
  - SLC2A2
  - SLC27A1
genes:
- word: INS
  symbol: INS
  source: hgnc_symbol
  hgnc_symbol: INS
  entrez: '3630'
- word: INS
  symbol: INS
  source: hgnc_symbol
  hgnc_symbol: INS
  entrez: '3630'
- word: INS-R
  symbol: INSR
  source: hgnc_symbol
  hgnc_symbol: INSR
  entrez: '3643'
- word: INS-R
  symbol: INSR
  source: hgnc_symbol
  hgnc_symbol: INSR
  entrez: '3643'
- word: (IRS2)
  symbol: IRS2
  source: hgnc_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: (IRS2)
  symbol: IRS2
  source: hgnc_symbol
  hgnc_symbol: IRS2
  entrez: '8660'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: (PI3k)
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: (AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: (AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: (AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3k
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: CHREBP
  symbol: CHREBP
  source: hgnc_alias_symbol
  hgnc_symbol: MLXIPL
  entrez: '51085'
- word: DNL
  symbol: DNL
  source: hgnc_prev_symbol
  hgnc_symbol: DNASE2
  entrez: '1777'
- word: GLUT2
  symbol: GLUT2
  source: hgnc_prev_symbol
  hgnc_symbol: SLC2A2
  entrez: '6514'
- word: FATP
  symbol: FATP
  source: hgnc_alias_symbol
  hgnc_symbol: SLC27A1
  entrez: '376497'
chemicals: []
diseases: []
figid_alias: PMC7305712__F2
redirect_from: /figures/PMC7305712__F2
figtype: Figure
---
